Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity
Daofeng Liu, … , Gianpietro Dotti, Leonid S. Metelitsa
Daofeng Liu, … , Gianpietro Dotti, Leonid S. Metelitsa
Published May 8, 2012
Citation Information: J Clin Invest. 2012;122(6):2221-2233. https://doi.org/10.1172/JCI59535.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 10

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity

  • Text
  • PDF
Abstract

Vα24-invariant NKT cells inhibit tumor growth by targeting tumor-associated macrophages (TAMs). Tumor progression therefore requires that TAMs evade NKT cell activity through yet-unknown mechanisms. Here we report that a subset of cells in neuroblastoma (NB) cell lines and primary tumors expresses membrane-bound TNF-α (mbTNF-α). These proinflammatory tumor cells induced production of the chemokine CCL20 from TAMs via activation of the NF-κB signaling pathway, an effect that was amplified in hypoxia. Flow cytometry analyses of human primary NB tumors revealed selective accumulation of CCL20 in TAMs. Neutralization of the chemokine inhibited in vitro migration of NKT cells toward tumor-conditioned hypoxic monocytes and localization of NKT cells to NB grafts in mice. We also found that hypoxia impaired NKT cell viability and function. Thus, CCL20-producing TAMs served as a hypoxic trap for tumor-infiltrating NKT cells. IL-15 protected antigen-activated NKT cells from hypoxia, and transgenic expression of IL-15 in adoptively transferred NKT cells dramatically enhanced their antimetastatic activity in mice. Thus, tumor-induced chemokine production in hypoxic TAMs and consequent chemoattraction and inhibition of NKT cells represents a mechanism of immune escape that can be reversed by adoptive immunotherapy with IL-15–transduced NKT cells.

Authors

Daofeng Liu, Liping Song, Jie Wei, Amy N. Courtney, Xiuhua Gao, Ekaterina Marinova, Linjie Guo, Andras Heczey, Shahab Asgharzadeh, Eugene Kim, Gianpietro Dotti, Leonid S. Metelitsa

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 Total
Citations: 5 8 12 10 11 6 4 7 12 6 6 6 5 98
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (98)

Title and authors Publication Year
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment
Zong J, Li YR
Bioengineering 2025
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou JJ, Wang P, Chai-Ho W, Park S, Seet CS, Oliai C, Yang L
Nature Communications 2025
Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice
Zhenyu Dai, Zheng Zhu, Zhiyao Li, Lei Tian, Kun-Yu Teng, Hanyu Chen, Li-Shu Wang, Jianying Zhang, Laleh G Melstrom, Michael A. Caligiuri, Jianhua Yu
Journal of Clinical Investigation 2025
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function
Tian G, Barragan GA, Yu H, Martinez-Amador C, Adaikkalavan A, Rios X, Guo L, Drabek JM, Pardias O, Xu X, Montalbano A, Zhang C, Li Y, Courtney AN, Di Pierro EJ, Metelitsa LS
Cancer Immunology Research 2025
Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy
Li S, Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, zhang B, Yang Y, Shen X, Chen Y, Hsiai T, Yang L
Research Square 2025
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, Dellabona P, Genovese P, Savoldo B, Metelitsa LS, Dotti G
Nature Communications 2024
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, Carneiro BA
Oncogene 2024
T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells
Das R
Critical Reviews in Oncogenesis 2024
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method.
Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn ZS, Guo W, Cen X, Husman T, Bajpai A, Kramer A, Wilson M, Fang Y, Huang J, Li S, Zhou Y, Zhang Y, Hahn Z, Zhu E, Ma F, Pan C, Lusis AJ, Zhou JJ, Seet CS, Kohn DB, Wang P, Zhou XJ, Pellegrini M, Puliafito BR, Larson SM, Yang L
Nature Biotechnology 2024
Deficiency and dysfunctional roles of natural killer T cells in patients with ARDS
Park KJ, Kim TO, Cho YN, Jin HM, Jo YG, Shin HJ, Kho BG, Kee SJ, Park YW
Frontiers in Immunology 2024
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.
Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, Weng J, Du X, Wu K, Lai P
Journal of hematology & oncology 2024
Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments
Wu X, Fang S
Frontiers in Immunology 2024
A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses
Shi W, Xu W, Song L, Zeng Q, Qi G, Qin Y, Li Z, Liu X, Jiao Z, Zhao Y, Liu N, Lu H
Molecular Therapy 2024
Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
Iyoda T, Yamasaki S, Ueda S, Shimizu K, Fujii SI
Biomolecules 2023
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma.
Tomolonis JA, Xu X, Dholakia KH, Zhang C, Guo L, Courtney AN, Wang S, Balzeau J, Barragán GA, Tian G, Di Pierro EJ, Metelitsa LS
Journal for ImmunoTherapy of Cancer 2023
PTBP2-Mediated Alternative Splicing of IRF9 Controls Tumor-Associated Monocyte/Macrophage Chemotaxis and Repolarization in Neuroblastoma Progression
Tang J, He J, Guo H, Lin H, Li M, Yang T, Wang HY, Li D, Liu J, Li L, Xia H, Zhuo Z, Miao L
Research 2023
New cell sources for CAR-based immunotherapy
Mazinani M, Rahbarizadeh F
Biomarker Research 2023
Advancing Cell-Based Cancer Immunotherapy Through Stem Cell Engineering
Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L
Cell Stem Cell 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS
Nature Medicine 2023
Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.
Maryam S, Krukiewicz K, Haq IU, Khan AA, Yahya G, Cavalu S
Journal of Clinical Medicine 2023
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR
Cells 2023
Primary Mouse Invariant Natural Killer T (iNKT) Cell Purification and Transduction
Delfanti G, Dellabona P, Casorati G
Bio-protocol 2023
Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X
Journal of Hematology & Oncology 2023
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges
Zappa E, Vitali A, Anders K, Molenaar JJ, Wienke J, Künkele A
European Journal of Cancer 2023
Targeting the myeloid microenvironment in neuroblastoma.
Stip MC, Teeuwen L, Dierselhuis MP, Leusen JHW, Krijgsman D
Journal of experimental & clinical cancer research : CR 2023
iNKT: A new avenue for CAR-based cancer immunotherapy
Y Liu, G Wang, D Chai, Y Dang, J Zheng, H Li
Translational oncology 2022
The iNKT Cell–Macrophage Axis in Homeostasis and Disease
M Cruz, J Loureiro, M Oliveira, M Macedo
International journal of molecular sciences 2022
Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers
D Wu, X Liu, J Mu, J Yang, F Wu, H Zhou
Biomolecules 2022
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
Nelson A, Gebremeskel S, Lichty BD, Johnston B
Journal for ImmunoTherapy of Cancer 2022
Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment
Delfanti G, Dellabona P, Casorati G, Fedeli M
Frontiers in Medicine 2022
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SM, Rahbarizadeh F
Frontiers in immunology 2022
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T, Yu SK, Xiang Y, Lu KH, Sun M
Frontiers in immunology 2022
Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
Nguyen R, Zhang X, Sun M, Abbas S, Seibert C, Kelly MC, Shern JF, Thiele CJ
Clinical cancer research 2022
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
Courtney AN, Tian G, Metelitsa LS
Blood 2022
Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
Quach DH, Lulla P, Rooney CM
Blood 2022
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
A Nelson, JD Lukacs, B Johnston
Cancers 2021
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
M Bell, S Gottschalk
Frontiers in immunology 2021
Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma
YM Liao, TH Hung, JK Tung, J Yu, YL Hsu, JT Hung, AL Yu
Journal of Personalized Medicine 2021
Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review
KT Jin, WL Du, HR Lan, YY Liu, CS Mao, JL Du, XZ Mou
Cancer Science 2021
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities
F Akter, B Simon, NL de Boer, N Redjal, H Wakimoto, K Shah
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021
A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden
Z Starosolski, AN Courtney, M Srivastava, L Guo, I Stupin, LS Metelitsa, A Annapragada, KB Ghaghada, AP Kostikov
Contrast Media & Molecular Imaging 2021
Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma
Y Yu, Y Zeng, X Xia, JG Zhou, F Cao
Cancer control : journal of the Moffitt Cancer Center 2021
Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
F Morandi, F Sabatini, M Podestà, I Airoldi
Human vaccines 2021
Artificial Tumor Microenvironments in Neuroblastoma
CH Quinn, AM Beierle, EA Beierle
Cancers 2021
A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy
H Xu, IN Buhtoiarov, H Guo, NK Cheung
OncoImmunology 2021
The role of NKT cells in gastrointestinal cancers
Burks J, Olkhanud PB, Berzofsky JA
OncoImmunology 2021
Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
KO McNerney, SA Karageorgos, MD Hogarty, H Bassiri
Frontiers in immunology 2020
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
A Heczey, AN Courtney, A Montalbano, S Robinson, K Liu, M Li, N Ghatwai, O Dakhova, B Liu, T Raveh-Sadka, CN Chauvin-Fleurence, X Xu, H Ngai, EJ Pierro, B Savoldo, G Dotti, LS Metelitsa
Nature Medicine 2020
IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
A Trujillo-Ocampo, HW Cho, M Clowers, S Pareek, W Ruiz-Vazquez, SE Lee, JS Im
Frontiers in immunology 2020
“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
KX Liu, S Joshi
Frontiers in immunology 2020
Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment
S Malekghasemi, J Majidi, A Baghbanzadeh, J Abdolalizadeh, B Baradaran, L Aghebati-Maleki
Advanced pharmaceutical bulletin 2020
Editorial: NKT Cells in Cancer Immunotherapy
TJ Webb, W Yuan, E Meyer, P Dellabona
Frontiers in immunology 2020
Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor
S Paul, S Chhatar, A Mishra, G Lal
Journal for ImmunoTherapy of Cancer 2019
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer
Y Zhu, DJ Smith, Y Zhou, YR Li, J Yu, D Lee, YC Wang, SD Biase, , C Hardoy, J Ku, T Tsao, LJ Lin, AT Pham, H Moon, J McLaughlin, D Cheng, RP Hollis, B Campo-Fernandez, F Urbinati, L Wei, L Pang, V Rezek, B Berent-Maoz, MH Macabali, D Gjertson, X Wang, Z Galic, SG Kitchen, DS An, S Hu-Lieskovan, PJ Kaplan-Lefko, SN Oliveira, CS Seet, SM Larson, SJ Forman, JR Heath, JA Zack, GM Crooks, CG Radu, A Ribas, DB Kohn, ON Witte, L Yang
Cell Stem Cell 2019
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
X Xu, W Huang, A Heczey, D Liu, L Guo, M Wood, J Jin, AN Courtney, B Liu, EJ Pierro, J Hicks, GA Barragan, H Ngai, Y Chen, B Savoldo, G Dotti, LS Metelitsa
Clinical cancer research 2019
Human cord blood (hCB)-CD34+ humanized mice fail to reject human acute myeloid leukemia cells
O Tanaskovic, MV Falzacappa, PG Pelicci, CH Kim
PloS one 2019
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
KC Pituch, J Miska, G Krenciute, WK Panek, G Li, T Rodriguez-Cruz, M Wu, Y Han, MS Lesniak, S Gottschalk, IV Balyasnikova
Molecular Therapy 2018
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
BJ Wolf, JE Choi, MA Exley
Frontiers in immunology 2018
Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment
CM Wunderlich, PJ Ackermann, AL Ostermann, P Adams-Quack, MC Vogt, ML Tran, A Nikolajev, A Waisman, C Garbers, S Theurich, J Mauer, N Hövelmeyer, FT Wunderlich
Nature Communications 2018
The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues
F Cortesi, G Delfanti, G Casorati, P Dellabona
Frontiers in immunology 2018
Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
T Vanichapol, S Chutipongtanate, U Anurathapan, S Hongeng
BioMed Research International 2018
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors
F Pohl-Guimarães, C Yang, KA Dyson, TJ Wildes, J Drake, J Huang, C Flores, EJ Sayour, DA Mitchell
Molecular Therapy 2018
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma
L Fultang, LD Gamble, L Gneo, AM Berry, SA Egan, FD Bie, O Yogev, GL Eden, S Booth, S Brownhill, A Vardon, CM McConville, PN Cheng, MD Norris, HC Etchevers, J Murray, DS Ziegler, L Chesler, R Schmidt, SA Burchill, M Haber, CD Santo, F Mussai
Cancer research 2018
Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis
SK Lee, KK Park, HJ Kim, J Park, SH Son, KR Kim, WY Chung
Scientific Reports 2017
Humanized Mouse Models of Clinical Disease
NC Walsh, LL Kenney, S Jangalwe, KE Aryee, DL Greiner, MA Brehm, LD Shultz
Annual review of pathology 2017
Tumor-associated macrophages: implications in cancer immunotherapy
AJ Petty, Y Yang
Immunotherapy 2017
Modeling Natural Killer Cell Targeted Immunotherapies
S Lopez-Lastra, JP di Santo
Frontiers in immunology 2017
Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies
PY Lam, MD Nissen, SR Mattarollo
Frontiers in immunology 2017
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
T Shum, B Omer, H Tashiro, RL Kruse, DL Wagner, K Parikh, Z Yi, T Sauer, D Liu, R Parihar, P Castillo, H Liu, MK Brenner, LS Metelitsa, S Gottschalk, CM Rooney
Cancer Discovery 2017
Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
M Bedard, M Salio, V Cerundolo
Frontiers in immunology 2017
Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges: Cytotoxic lymphocytes and atherosclerosis
T Kyaw, K Peter, Y Li, P Tipping, BH Toh, A Bobik
British Journal of Pharmacology 2017
Targeting O -Acetyl-GD2 Ganglioside for Cancer Immunotherapy
J Fleurence, S Fougeray, M Bahri, D Cochonneau, B Clémenceau, F Paris, A Heczey, S Birklé
Journal of Immunology Research 2017
IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer
K Rohena-Rivera, MM Sánchez-Vázquez, DA Aponte-Colón, IS Forestier-Román, ME Quintero-Aguiló, M Martínez-Ferrer, A Ahmad
PloS one 2017
Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation
T Zhang, Y Liu, X Peng, J Fan, Z Peng
Disease Markers 2017
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, S Gottschalk
Cancer immunology research 2017
Human T effector cells are adapted to hypoxia through HIF1α and glycolytic metabolism
Yang Xu, Arindam Chaudhury, Ming Zhang, Barbara Savoldo, Leonid Metelitsa, John Rodgers, Jason Yustein, Joel Neilson, Gianpietro Dotti
Journal of Clinical Investigation 2016
Immunotherapeutic strategies targeting natural killer T cell responses in cancer
SC Shissler, DR Bollino, IV Tiper, JP Bates, R Derakhshandeh, TJ Webb
Immunogenetics 2016
Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression
P Guan, H Bassiri, NP Patel, KE Nichols, R Das
Bone Marrow Transplantation 2016
Tumor-infiltrating lymphocytes (TILs) from patients with glioma
Z Liu, Q Meng, J Bartek, T Poiret, O Persson, L Rane, E Rangelova, C Illies, IH Peredo, X Luo, MV Rao, RA Robertson, E Dodoo, M Maeurer
OncoImmunology 2016
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
AH Long, SL Highfill, Y Cui, JP Smith, AJ Walker, S Ramakrishna, R El-Etriby, S Galli, MG Tsokos, RJ Orentas, CL Mackall
Cancer immunology research 2016
Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia: Table 1
JS Brown
Schizophrenia Bulletin 2016
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
F Mussai, S Egan, S Hunter, H Webber, J Fisher, R Wheat, C McConville, Y Sbirkov, K Wheeler, G Bendle, K Petrie, J Anderson, L Chesler, CD Santo
Cancer research 2015
Neuroblastoma: Molecular Pathogenesis and Therapy
CU Louis, JM Shohet
Annual Review of Medicine 2015
Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model
L Chakrabarti, C Morgan, AD Sandler, X Bai
PloS one 2015
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32
Markus Maeurer, Martin Rao, Alimuddin Zumla
Annals of translational medicine 2015
Invariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer Comorbidity
G Gaoatswe, BD Kent, MA Corrigan, G Nolan, AE Hogan, WT McNicholas, D O'Shea
Sleep 2015
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
K Pilipow, A Roberto, M Roederer, TA Waldmann, D Mavilio, E Lugli
Cancer research 2015
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Andras Heczey, Daofeng Liu, Gengwen Tian, Amy N Courtney, Jie Wei, Ekaterina Marinova, Xiuhua Gao, Linjie Guo, Eric Yvon, John Hicks, Hao Liu, Gianpietro Dotti, Leonid S Metelitsa
Blood 2014
Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues
EV Overmeire, D Laoui, J Keirsse, JA van Ginderachter, A Sarukhan
Frontiers in immunology 2014
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases
M Terabe, JA Berzofsky
Cancer Immunology, Immunotherapy 2014
Human Cancer Growth and Therapy in Immunodeficient Mouse Models
LD Shultz, N Goodwin, F Ishikawa, V Hosur, BL Lyons, DL Greiner
Cold Spring Harbor Protocols 2014
Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
E Gomes-Giacoia, M Miyake, S Goodison, A Sriharan, G Zhang, L You, JO Egan, PR Rhode, AS Parker, KX Chai, HC Wong, CJ Rosser
PloS one 2014
GD2-Targeted Immunotherapy and Radioimmunotherapy
K Dobrenkov, NK Cheung
Seminars in Oncology 2014
The tumor microenvironment: a pitch for multiple players
G Schiavoni, L Gabriele, F Mattei
Frontiers in Oncology 2013
Immunosuppressive microenvironment in neuroblastoma
V Pistoia, F Morandi, G Bianchi, A Pezzolo, I Prigione, L Raffaghello
Frontiers in Oncology 2013
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
NK Cheung, MA Dyer
Nature Reviews Cancer 2013
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
C Arber, H Abhyankar, HE Heslop, MK Brenner, H Liu, G Dotti, B Savoldo
Gene Therapy 2013
Differential expression and TNF-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas
JL Oliver, MP Alexander, AG Norrod, IM Mullins, DW Mullins
Pigment Cell & Melanoma Research 2013

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
Referenced in 12 patents
170 readers on Mendeley
See more details